MedTrace Logo

FASENRA Regulatory Postmarketing Surveillance in Korea

NCT05091333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2026-02-06

No results posted yet for this study

Summary

As part of a post approval commitment, the MFDS has requested a study to characterize safety in patients who are treated with FASENRA for severe eosinophilic asthma and/or eosinophilic granulomatosis with polyangiitis (EGPA) by physicians in normal clinical practice settings. This study is designed to confirm or assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of FASENRA under conditions of routine daily medical practice in Korea.

Conditions

  • Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-11
Primary Completion
2025-03-06
Completion
2025-03-06

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05091333 on ClinicalTrials.gov